檢索結果 - Gopalakrishna, Prashanth

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

    Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy 由 Vahdat, Linda T., Garcia, Agustin A., Vogel, Charles, Pellegrino, Christine, Lindquist, Deborah L., Iannotti, Nicholas, Gopalakrishna, Prashanth, Sparano, Joseph A.

    出版 2013
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  2. 2
    The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

    The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies 由 Gupta, Vikas, Harrison, Claire, Hexner, Elizabeth O., Al-Ali, Haifa Kathrin, Foltz, Lynda, Montgomery, Michael, Sun, William, Gopalakrishna, Prashanth, Kantarjian, Hagop, Verstovsek, Srdan

    出版 2016
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  3. 3
    Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

    Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses 由 Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

    出版 2017
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  4. 4
    The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

    The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitini... 由 McMullin, Mary Frances, Harrison, Claire N., Niederwieser, Dietger, Demuynck, Hilde, Jäkel, Nadja, Gopalakrishna, Prashanth, McQuitty, Mari, Stalbovskaya, Viktoriya, Recher, Christian, Theunissen, Koen, Gisslinger, Heinz, Kiladjian, Jean-Jacques, Al-Ali, Haifa-Kathrin

    出版 2015
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  5. 5
    A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

    A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 由 Vannucchi, Alessandro M., Kantarjian, Hagop M., Kiladjian, Jean-Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A., Sarlis, Nicholas J., Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan

    出版 2015
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:
  6. 6
    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

    Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study 由 Ross, David M., Masszi, Tamas, Gómez Casares, María Teresa, Hellmann, Andrzej, Stentoft, Jesper, Conneally, Eibhlin, Garcia-Gutierrez, Valentin, Gattermann, Norbert, le Coutre, Philipp D., Martino, Bruno, Saussele, Susanne, Giles, Francis J., Radich, Jerald P., Saglio, Giuseppe, Deng, Weiping, Krunic, Nancy, Bédoucha, Véronique, Gopalakrishna, Prashanth, Hochhaus, Andreas

    出版 2018
    獲取全文 獲取全文 獲取全文
    Text
    加到收藏夾
    Saved in:

檢索工具: